Miklos Pless
Overview
Explore the profile of Miklos Pless including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
82
Citations
2779
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stoffel S, Bhadhuri A, Salari P, Koeberle D, Koessler T, Siebenhuner A, et al.
BMJ Open
. 2025 Feb;
15(2):e090401.
PMID: 39987014
Objectives: Our study investigated the impact of oesophageal cancer and its treatments on work productivity, leisure time, household chores and informal care in Switzerland. We assessed indirect costs for patients...
2.
Tokito T, Kolesnik O, Sorensen J, Artac M, Lazaro Quintela M, Lee J, et al.
BMC Cancer
. 2024 Jul;
23(Suppl 1):1251.
PMID: 39054476
Background: Pembrolizumab is a first-line therapy for certain patients with advanced/metastatic non-small cell lung cancer (NSCLC). Combining pembrolizumab with other immunotherapies may enhance tumor cell killing and clinical outcomes. Epacadostat...
3.
Leal T, Kotecha R, Ramlau R, Zhang L, Milanowski J, Cobo M, et al.
Lancet Oncol
. 2023 Sep;
24(9):1002-1017.
PMID: 37657460
Background: Tumor Treating Fields (TTFields) are electric fields that disrupt processes critical for cancer cell survival, leading to immunogenic cell death and enhanced antitumour immune response. In preclinical models of...
4.
Meinlschmidt G, Grossert A, Meffert C, Roemmel N, Hess V, Rochlitz C, et al.
JMIR Cancer
. 2023 Aug;
9:e38515.
PMID: 37639296
Background: Cancer is related to not only physical but also mental suffering. Notably, body image disturbances are highly relevant to cancer-related changes often persisting beyond recovery from cancer. Scalable and...
5.
Hanna N, Shepherd F, Fossella F, Pereira J, de Marinis F, von Pawel J, et al.
J Clin Oncol
. 2023 May;
41(15):2682-2690.
PMID: 37196429
Purpose: To compare the efficacy and toxicity of pemetrexed versus docetaxel in patients with advanced non-small-cell lung cancer (NSCLC) previously treated with chemotherapy. Patients And Methods: Eligible patients had a...
6.
Grossert A, Meffert C, Hess V, Rochlitz C, Pless M, Hunziker S, et al.
Front Psychol
. 2023 Apr;
14:956493.
PMID: 37089722
Introduction: Cancer-related impairments often co-occur with bodily disturbances. Body psychotherapy (BPT) can improve bodily wellbeing, yet evidence in cancer survivors is scarce. Hence, we aimed to evaluate whether blended group...
7.
Hayoz S, Kasenda B, Schenker A, Kopp C, Schar S, Thurlimann B, et al.
BMJ Open
. 2023 Apr;
13(4):e068490.
PMID: 37072360
Background: Premature trial discontinuation and non-publication of trial results are still major issues negatively affecting reliable evidence generation. Objectives: To investigate trial completion and publication rate of cancer trials conducted...
8.
Nie R, Chen F, Provencio M, Wang Y, Ende T, van Laarhoven H, et al.
Eur J Cancer
. 2023 Apr;
186:211-221.
PMID: 37062625
Background: An increasing number of clinical trials are being conducted exploring the efficacy of neoadjuvant immune checkpoint inhibitors. Surrogate end-points for overall survival (OS) are urgently needed. Methods: Phase II...
9.
Hetzel J, Mauti L, Winkler J, Cardoso Almeida S, Jermann P, Pless M, et al.
J Clin Med
. 2023 Mar;
12(6).
PMID: 36983354
Personalized treatment of metastatic non-squamous non-small cell lung cancer (NSCLC) requires detailed molecular characterization of the tumour including detection of predictive driver mutations and programmed death ligand 1 (PD-L1) expression....
10.
Storck L, Uster A, Gafner L, Ruehlin M, Gaeumann S, Gisi D, et al.
Front Nutr
. 2023 Mar;
10:1063279.
PMID: 36937336
Background And Aims: Although many cancer patients suffer from malnutrition or cancer cachexia, there is no standard of care so far due to limited intervention trials. Pooled data from two...